信達生物(01801.HK)與BOLT合作開發三款藥物
信達生物(01801.HK)公布,與Bolt Biotherapeutics達成新藥研究開發協議,將共同開發三款治療腫瘤的抗體-免疫刺激偶聯物(「ISAC」)候選藥物。Boltbody ISAC平台由靶向腫瘤抗體、穩定且不可降解的連接子(linker)和專有免疫刺激劑組成,結合了抗體靶向腫瘤的精確性與先天性和適應性免疫系統反應的作用。
Bolt為一家處於臨床階段的生物技術公司,其開創了一種能有效結合抗體靶向的精確性與先天性和適應性免疫系統的新型免疫療法。
根據協議條款,公司將擁有三個合作項目的大中華區權益,同時保留其中一個項目的全球權益、另一項目除北美外區域權益的選擇權。Bolt保留其中一個項目除大中華外區域權益的選擇權和另一個項目的北美區域權益。公司將承擔至臨床概念驗證(POC, proof-of-concept)期間的所有研發費用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.